Aged
Cardiac Output, Low
Cardiotonic Agents
Cost-Benefit Analysis
Dobutamine
Double-Blind Method
Europe
Female
Follow-Up Studies
Heart Failure
Humans
Hydrazones
Infusions, Intravenous
Length of Stay
Life Expectancy
Male
Middle Aged
Patient Admission
Pyridazines
Randomized Controlled Trials as Topic
Risk Factors
Sensitivity and Specificity
Severity of Illness Index
Survival Analysis
Treatment Outcome
